Thrombophilia is the term used to describe an hereditary or acquired predisposition to thromboembolism (the formation of a venous clot), which manifests itself as either deep vein thrombosis (DVT) or pulmonary embolism (PE). The presence of thrombophilia can be tested and many people with venous thrombosis or pulmonary embolism nowadays have their blood tested for a deficiency in natural anticoagulants such as antithrombin, protein C, or protein S. However, the benefits of these costly tests are uncertain. The most important benefit would be a reduction in the risk of developing a new venous clot by taking preventative measures. To date no high quality trials have assessed this issue.
閱讀完整摘要
Tests for thrombophilia are being performed on a large scale in people after venous thromboembolism (VTE) even though the benefits of testing are still subject to debate. The most important benefit would be a reduction in the risk of recurrent VTE due to the use of additional prophylactic measures. This is an update of a review first published in 2009.
目的
The objective of this review was to assess the benefit of testing for thrombophilia after VTE in terms of risk reduction of recurrent VTE.
搜尋策略
For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 21 2012) and CENTRAL (2012, Issue 5). The authors searched MEDLINE and EMBASE.
選擇標準
Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that compared the rate of recurrent VTE in participants with VTE who were tested for thrombophilia with the rate in participants with VTE who were not tested were eligible.
資料收集與分析
We planned to extract data from identified studies using data extraction forms.
主要結果
No studies were included because no RCTs or CCTs could be identified.
作者結論
There are currently no randomized controlled trials or controlled clinical trials that have assessed the benefit(s) of testing for thrombophilia on the risk of recurrent VTE.
